{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:11:53Z","timestamp":1775470313442,"version":"3.50.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","award":["2024GXNSFAA010018"],"award-info":[{"award-number":["2024GXNSFAA010018"]}],"id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Vitiligo is a clinically prevalent acquired skin disorder characterized by depigmentation. Currently, the therapeutic options for vitiligo are restricted, and numerous issues exist, such as a prolonged treatment course, unsatisfactory therapeutic efficacy, adverse reactions and a high propensity for recurrence after treatment cessation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the safety and efficacy of combined treatment involving oral tofacitinib citrate (TC) and a 308-nm excimer laser (EL), with the aim of discovering a rapid and effective treatment approach to minimize the side-effects of various drugs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In total, 63 patients with progressive vitiligo and a Vitiligo Disease Activity Score of 4 from January 2022 to January 2024 were enrolled and divided into three groups. The three groups were: the TC combined with 308-nm EL and methylprednisolone treatment group (group 1); the TC and 308-nm EL treatment group (group 2); and the methylprednisolone alone treatment group (group 3). The treatment was continued for 24 weeks, and an assessment of therapy outcomes was performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>When TC was combined with 308-nm EL and methylprednisolone treatment (group 1), the effect was more rapid than in the other two groups. When TC was combined with 308-nm EL (group 2), it had a more favourable treatment effect than that of methylprednisolone alone (group 3), despite having a slower onset of effect. After 24 weeks of treatment, there was no significant difference between group 1 and group 2 in terms of the total response rate or significant response. However, when only methylprednisolone treatment was applied, the effect was relatively slow and ineffective.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study confirmed a rapid and effective treatment of vitiligo was achieved through a combination of TC and 308-nm EL. No serious adverse reactions were reported, and therefore this could potentially offer an optimal treatment plan for patients with vitiligo.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae532","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T23:33:01Z","timestamp":1733873581000},"page":"940-945","source":"Crossref","is-referenced-by-count":1,"title":["Combined tofacitinib citrate and 308-nm excimer laser treatment for vitiligo: a pilot study"],"prefix":"10.1093","volume":"50","author":[{"given":"Jia","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Dermatology, People's Hospital of Guangxi Zhuang Autonomous Region , Nanning ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuting","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, People's Hospital of Guangxi Zhuang Autonomous Region , Nanning ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, People's Hospital of Guangxi Zhuang Autonomous Region , Nanning ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siguang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, People's Hospital of Guangxi Zhuang Autonomous Region , Nanning ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, People's Hospital of Guangxi Zhuang Autonomous Region , Nanning ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, People's Hospital of Guangxi Zhuang Autonomous Region , Nanning ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhen","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, People's Hospital of Guangxi Zhuang Autonomous Region , Nanning ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, People's Hospital of Guangxi Zhuang Autonomous Region , Nanning ,","place":["PR China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"2025042411075406300_llae532-B1","doi-asserted-by":"crossref","first-page":"e0163806","DOI":"10.1371\/journal.pone.0163806","article-title":"The prevalence of vitiligo: a meta-\u00adanalysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PLOS ONE"},{"key":"2025042411075406300_llae532-B2","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"2025042411075406300_llae532-B3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: a review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"2025042411075406300_llae532-B4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/phpp.12598","article-title":"Development of evidence-based consensus on critical issues in the management of patients with vitiligo: a modified Delphi study","volume":"37","author":"Bae","year":"2021","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2025042411075406300_llae532-B5","first-page":"65","article-title":"Pigment Disease Group of Dermatology and Venereology Professional Committee of Chinese Association of Integrative Medicine. [Vitiligo clinical classification and efficacy standards (revised in 2003)]","volume":"3","year":"2004","journal-title":"Chinese J Dermatovenereol Integr Trad West Med"},{"key":"2025042411075406300_llae532-B6","doi-asserted-by":"crossref","first-page":"e20154126","DOI":"10.1542\/peds.2015-4126","article-title":"A practical approach to the diagnosis and treatment of vitiligo in children","volume":"138","author":"Ezzedine","year":"2016","journal-title":"Pediatrics"},{"key":"2025042411075406300_llae532-B7","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/jdv.19450","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international Vitiligo Task Force\u00a0\u2013 \u200cPart 2: specific treatment recommendations","volume":"37","author":"Seneschal","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042411075406300_llae532-B8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054910","article-title":"Vitiligo, from pathogenesis to therapeutic advances: state of the art","volume":"24","author":"Diotallevi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025042411075406300_llae532-B9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14740338.2020.1729737","article-title":"Safety of the current drug treatments for vitiligo","volume":"19","author":"Lotti","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"2025042411075406300_llae532-B10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025042411075406300_llae532-B11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamadermatol.2020.0218","article-title":"Evaluation for skin cancer and precancer in patients with vitiligo treated with long-term narrowband UV-B phototherapy","volume":"156","author":"Bae","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025042411075406300_llae532-B12","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/jdv.18005","article-title":"The use of lasers in vitiligo, an overview","volume":"36","author":"Post","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042411075406300_llae532-B13","doi-asserted-by":"crossref","first-page":"10409","DOI":"10.3390\/ijms221910409","article-title":"A lower irradiation dose of 308\u2005nm monochromatic excimer light might be sufficient for vitiligo treatment: a novel insight gained from in vitro and in vivo analyses","volume":"22","author":"Kuroda","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025042411075406300_llae532-B14","doi-asserted-by":"crossref","first-page":"e35533","DOI":"10.1097\/MD.0000000000035533","article-title":"Efficacy and safety of compound glycyrrhizin in combination with conventional therapy in treatment of vitiligo: a systematic review and meta-analysis of randomized controlled trials","volume":"102","author":"Jian","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"2025042411075406300_llae532-B15","doi-asserted-by":"crossref","first-page":"e5354","DOI":"10.1590\/1414-431x20165354","article-title":"Combination therapy of orally administered glycyrrhizin and UVB improved active-stage generalized vitiligo","volume":"49","author":"Mou","year":"25 2016","journal-title":"Braz J Med Biol Res"},{"key":"2025042411075406300_llae532-B16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"2025042411075406300_llae532-B17","doi-asserted-by":"crossref","first-page":"986918","DOI":"10.3389\/fimmu.2022.986918","article-title":"Advances in vitiligo: update on therapeutic targets","volume":"13","author":"Feng","year":"2022","journal-title":"Front Immunol"},{"key":"2025042411075406300_llae532-B18","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1111\/1346-8138.16911","article-title":"Efficacy of intralesional corticosteroid injections for scalp vitiligo: an effective therapeutic option","volume":"50","author":"Wang","year":"2023","journal-title":"J Dermatol"},{"key":"2025042411075406300_llae532-B19","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/jdv.19162","article-title":"Topical ruxolitinib: a new treatment for vitiligo","volume":"37","author":"Tavoletti","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042411075406300_llae532-B20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-4632.2012.05697.x","article-title":"Efficacy of topical calcineurin inhibitors in vitiligo","volume":"52","author":"Wong","year":"2013","journal-title":"Int J Dermatol"},{"key":"2025042411075406300_llae532-B21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1089\/thy.2010.1643","article-title":"Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease","volume":"20","author":"Spritz","year":"2010","journal-title":"Thyroid"},{"key":"2025042411075406300_llae532-B22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/bjd.12166","article-title":"Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms","volume":"168","author":"Gey","year":"2013","journal-title":"Br J Dermatol"},{"key":"2025042411075406300_llae532-B23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.25122\/jml-2019-0134","article-title":"Vitiligo and chronic autoimmune thyroiditis","volume":"14","author":"Sandru","year":"2021","journal-title":"J Med Life"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae532\/60989003\/llae532.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/5\/940\/60989003\/llae532.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/5\/940\/60989003\/llae532.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T15:08:02Z","timestamp":1745507282000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/5\/940\/7919228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,12,9]]},"published-print":{"date-parts":[[2025,4,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae532","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,12,9]]}}}